Table of Content
Table of Contents
Global Duchenne Muscular Dystrophy Drugs Market Report 2024, Forecast to 2031
1 Scope of the Study
1.1 Duchenne Muscular Dystrophy Drugs Introduction
1.2 Research Programs
1.3 Analysis of Macroeconomic Indicators
1.4 Years Considered
1.5 Methodology
1.6 Data Source
1.7 Research Objectives
2 Duchenne Muscular Dystrophy Drugs Industry Overview
2.1 Global Duchenne Muscular Dystrophy Drugs Market Size (Million USD) Comparison by Regions (2024-2031)
2.1.1 Duchenne Muscular Dystrophy Drugs Global Import Market Analysis
2.1.2 Duchenne Muscular Dystrophy Drugs Global Export Market Analysis
2.1.3 Duchenne Muscular Dystrophy Drugs Global Main Region Market Analysis
2.2 Market Analysis by Type
2.2.1 Development & Drug Target
2.2.2 Mechanism of Action (MoA)
2.2.3 Route of Administration (RoA)
2.2.4 Molecule Type
2.3 Market Analysis by Application
2.3.1 Hospitals and Clinics
2.3.2 Medical Laboratories
2.3.3 Others
2.4 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Market Share by Manufacturer
2.4.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Manufacturer (2019-2023)
2.4.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Manufacturer (2019-2023)
2.4.3 Global Duchenne Muscular Dystrophy Drugs Industry Concentration Ratio (CR5 and HHI)
2.4.4 Top 5 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share
2.4.5 Top 10 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share
2.4.6 Date of Key Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
2.4.7 Key Manufacturers Duchenne Muscular Dystrophy Drugs Product Offered
2.4.8 Mergers & Acquisitions Planning
2.5 Duchenne Muscular Dystrophy Drugs Historical Development Overview
2.6 Market Dynamics
2.6.1 Market Opportunities
2.6.2 Market Risk
2.6.3 Market Driving Force
2.6.4 Porter's Five Forces Analysis
2.7 Coronavirus Disease 2019 (Covid-19): Duchenne Muscular Dystrophy Drugs Industry Impact
2.7.1 How the Covid-19 is Affecting the Duchenne Muscular Dystrophy Drugs Industry
2.7.2 Duchenne Muscular Dystrophy Drugs Business Impact Assessment - Covid-19
2.7.3 Market Trends and Duchenne Muscular Dystrophy Drugs Potential Opportunities in the COVID-19 Landscape
2.7.4 Measures / Proposal against Covid-19
3 Upstream and Downstream Market Analysis
3.1 Upstream Analysis
3.1.1 Macro Analysis of Upstream Markets
3.1.2 Key Players in Upstream Markets
3.1.3 Upstream Market Trend Analysis
3.1.4 Duchenne Muscular Dystrophy Drugs Manufacturing Cost Analysis
3.2 Downstream Market Analysis
3.2.1 Macro Analysis of Down Markets
3.2.2 Key Players in Down Markets
3.2.3 Downstream Market Trend Analysis
3.2.4 Sales Channel, Distributors, Traders and Dealers
4 Global Duchenne Muscular Dystrophy Drugs Market Size Categorized by Regions
4.1 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Market Share by Regions
4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Regions (2019-2023)
4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Regions (2019-2023)
4.2 Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
4.3 APAC Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
4.4 North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
4.5 South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
4.6 Middle East & Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
5 Europe Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
5.1 Europe Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
5.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Countries (2019-2023)
5.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Countries (2019-2023)
5.1.3 Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
5.1.4 UK Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
5.1.5 France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
5.1.6 Russia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
5.1.7 Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
5.1.8 Spain Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
5.2 Europe Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2019-2023)
5.3 Europe Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2019-2023)
5.3.1 Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2019-2023)
5.3.2 Europe Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2019-2023)
5.4 Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2019-2023)
6 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
6.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
6.1.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales by Countries (2019-2023)
6.1.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue by Countries (2019-2023)
6.1.3 China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
6.1.4 Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
6.1.5 Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
6.1.6 India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
6.1.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
6.1.8 Australia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
6.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Revenue (Value) by Manufacturers (2019-2023)
6.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2019-2023)
6.3.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2019-2023)
6.3.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2019-2023)
6.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Market Share by Application (2019-2023)
7 North America Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
7.1 North America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
7.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Countries (2019-2023)
7.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2019-2023)
7.1.3 United States Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
7.1.4 Canada Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
7.1.5 Mexico Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
7.2 North America Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2019-2023)
7.3 North America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2019-2023)
7.3.1 North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2019-2023)
7.3.2 North America Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2019-2023)
7.4 North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2019-2023)
8 South America Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
8.1 South America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Duchenne Muscular Dystrophy Drugs Sales by Countries (2019-2023)
8.1.2 South America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2019-2023)
8.1.3 Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
8.2 South America Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2019-2023)
8.3 South America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2019-2023)
8.3.1 South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2019-2023)
8.3.2 South America Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2019-2023)
8.4 South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2019-2023)
9 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
9.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Countries (2019-2023)
9.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Countries (2019-2023)
9.1.3 GCC Countries Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
9.1.4 Turkey Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
9.1.5 Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
9.1.6 South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2019-2023)
9.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2019-2023)
9.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type
9.3.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2019-2023)
9.3.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2019-2023)
9.4 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2019-2023)
10 Global Duchenne Muscular Dystrophy Drugs Market Segment by Type
10.1 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Market Share by Type (2019-2023)
10.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Type (2019-2023)
10.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Type (2019-2023)
10.2 Development & Drug Target Sales Growth Rate and Price
10.2.1 Global Development & Drug Target Sales Growth Rate (2019-2023)
10.2.2 Global Development & Drug Target Price (2019-2023)
10.3 Mechanism of Action (MoA) Sales Growth Rate and Price
10.3.1 Global Mechanism of Action (MoA) Sales Growth Rate (2019-2023)
10.3.2 Global Mechanism of Action (MoA) Price (2019-2023)
10.4 Route of Administration (RoA) Sales Growth Rate and Price
10.4.1 Global Route of Administration (RoA) Sales Growth Rate (2019-2023)
10.4.2 Global Route of Administration (RoA) Price (2019-2023)
10.5 Molecule Type Sales Growth Rate and Price
10.5.1 Global Molecule Type Sales Growth Rate (2019-2023)
10.5.2 Global Molecule Type Price (2019-2023)
11 Global Duchenne Muscular Dystrophy Drugs Market Segment by Application
11.1 Global Duchenne Muscular Dystrophy DrugsSales Market Share by Application (2019-2023)
11.2 Hospitals and Clinics Sales Growth Rate (2019-2023)
11.3 Medical Laboratories Sales Growth Rate (2019-2023)
11.4 Others Sales Growth Rate (2019-2023)
12 Market Forecast for Duchenne Muscular Dystrophy Drugs
12.1 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Growth Rate (2024-2031)
12.2 Duchenne Muscular Dystrophy Drugs Market Forecast by Regions (2024-2031)
12.2.1 Europe Duchenne Muscular Dystrophy Drugs Market Forecast (2024-2031)
12.2.2 APAC Duchenne Muscular Dystrophy Drugs Market Forecast (2024-2031)
12.2.3 North America Duchenne Muscular Dystrophy Drugs Market Forecast (2024-2031)
12.2.4 South America Duchenne Muscular Dystrophy Drugs Market Forecast (2024-2031)
12.2.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2024-2031)
12.3 Duchenne Muscular Dystrophy Drugs Market Forecast by Type (2024-2031)
12.3.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2024-2031)
12.3.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2024-2031)
12.4 Duchenne Muscular Dystrophy Drugs Market Forecast by Application (2024-2031)
12.4.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2024-2031)
12.4.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2024-2031)
13 Analysis of Duchenne Muscular Dystrophy Drugs Industry Key Manufacturers
13.1 Akashi Therapeutics Inc
13.1.1 Company Details
13.1.2 Product Information
13.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.1.4 Main Business Overview
13.1.5 Akashi Therapeutics Inc News
13.2 Antisense Therapeutics Ltd
13.2.1 Company Details
13.2.2 Product Information
13.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.2.4 Main Business Overview
13.2.5 Antisense Therapeutics Ltd News
13.3 Beech Tree Labs Inc
13.3.1 Company Details
13.3.2 Product Information
13.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.3.4 Main Business Overview
13.3.5 Beech Tree Labs Inc News
13.4 Biogen Inc
13.4.1 Company Details
13.4.2 Product Information
13.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.4.4 Main Business Overview
13.4.5 Biogen Inc News
13.5 Bioleaders Corp
13.5.1 Company Details
13.5.2 Product Information
13.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.5.4 Main Business Overview
13.5.5 Bioleaders Corp News
13.6 BioMarin Pharmaceutical Inc
13.6.1 Company Details
13.6.2 Product Information
13.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.6.4 Main Business Overview
13.6.5 BioMarin Pharmaceutical Inc News
13.7 Biophytis SAS
13.7.1 Company Details
13.7.2 Product Information
13.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.7.4 Main Business Overview
13.7.5 Biophytis SAS News
13.8 Capricor Therapeutics Inc
13.8.1 Company Details
13.8.2 Product Information
13.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.8.4 Main Business Overview
13.8.5 Capricor Therapeutics Inc News
13.9 Catabasis Pharmaceuticals Inc
13.9.1 Company Details
13.9.2 Product Information
13.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.9.4 Main Business Overview
13.9.5 Catabasis Pharmaceuticals Inc News
13.10 CRISPR Therapeutics
13.10.1 Company Details
13.10.2 Product Information
13.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.10.4 Main Business Overview
13.10.5 CRISPR Therapeutics News
13.11 Cumberland Pharmaceuticals Inc
13.11.1 Company Details
13.11.2 Product Information
13.11.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.11.4 Main Business Overview
13.11.5 Cumberland Pharmaceuticals Inc News
13.12 Daiichi Sankyo Co Ltd
13.12.1 Company Details
13.12.2 Product Information
13.12.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.12.4 Main Business Overview
13.12.5 Daiichi Sankyo Co Ltd News
13.13 Debiopharm International SA
13.13.1 Company Details
13.13.2 Product Information
13.13.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.13.4 Main Business Overview
13.13.5 Debiopharm International SA News
13.14 Editas Medicine Inc
13.14.1 Company Details
13.14.2 Product Information
13.14.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.14.4 Main Business Overview
13.14.5 Editas Medicine Inc News
13.15 Eloxx Pharmaceuticals Inc
13.15.1 Company Details
13.15.2 Product Information
13.15.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.15.4 Main Business Overview
13.15.5 Eloxx Pharmaceuticals Inc News
13.16 F. Hoffmann-La Roche Ltd
13.16.1 Company Details
13.16.2 Product Information
13.16.3 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.16.4 Main Business Overview
13.16.5 F. Hoffmann-La Roche Ltd News
13.17 FibroGen Inc
13.17.1 Company Details
13.17.2 Product Information
13.17.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.17.4 Main Business Overview
13.17.5 FibroGen Inc News
13.18 Fulcrum Therapeutics Inc
13.18.1 Company Details
13.18.2 Product Information
13.18.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.18.4 Main Business Overview
13.18.5 Fulcrum Therapeutics Inc News
13.19 Galapagos NV
13.19.1 Company Details
13.19.2 Product Information
13.19.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.19.4 Main Business Overview
13.19.5 Galapagos NV News
13.20 Genethon SA
13.20.1 Company Details
13.20.2 Product Information
13.20.3 Genethon SA Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.20.4 Main Business Overview
13.20.5 Genethon SA News
13.21 GTx Inc
13.21.1 Company Details
13.21.2 Product Information
13.21.3 GTx Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.21.4 Main Business Overview
13.21.5 GTx Inc News
13.22 Santhera Pharmaceuticals Holding AG
13.22.1 Company Details
13.22.2 Product Information
13.22.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.22.4 Main Business Overview
13.22.5 Santhera Pharmaceuticals Holding AG News
13.23 Sarepta Therapeutics Inc
13.23.1 Company Details
13.23.2 Product Information
13.23.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.23.4 Main Business Overview
13.23.5 Sarepta Therapeutics Inc News
13.24 SOM Biotech SL
13.24.1 Company Details
13.24.2 Product Information
13.24.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.24.4 Main Business Overview
13.24.5 SOM Biotech SL News
13.25 Strykagen Corp
13.25.1 Company Details
13.25.2 Product Information
13.25.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.25.4 Main Business Overview
13.25.5 Strykagen Corp News
13.26 Summit Therapeutics Plc
13.26.1 Company Details
13.26.2 Product Information
13.26.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.26.4 Main Business Overview
13.26.5 Summit Therapeutics Plc News
13.27 Taiho Pharmaceutical Co Ltd
13.27.1 Company Details
13.27.2 Product Information
13.27.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.27.4 Main Business Overview
13.27.5 Taiho Pharmaceutical Co Ltd News
13.28 Teijin Pharma Ltd
13.28.1 Company Details
13.28.2 Product Information
13.28.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.28.4 Main Business Overview
13.28.5 News
13.29 WAVE Life Sciences Ltd
13.29.1 Company Details
13.29.2 Product Information
13.29.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
13.29.4 Main Business Overview
13.29.5 WAVE Life Sciences Ltd News
14 Research Findings and Conclusion
15 Appendix